Oscient Pharmaceuticals (OSCI) 8-K Genome Therapeutics Reports on Nasdaq Interpretation

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to

Section 13 or 15(d) of

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): February 2, 2004

GENOME THERAPEUTICS CORP.

(Exact name of registrant as specified in its charter)

Massachusetts	0-10824	04-2297484
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

100 Beaver Street

Waltham, Massachusetts 02453

(Address of principal executive offices, including zip code)

(781) 398-2300

(Registrant’s telephone number, including area code)

Page 1 of 4 pages.

ITEM 5.    OTHER EVENTS

On January 31, 2004, Genome Therapeutics Corp. issued a press release announcing Nasdaq’s interpretation regarding Genome’s registered common stock offering, which is attached hereto as Exhibit 99.1.

Item 7.    FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits

99.1    Press Release issued by Genome Therapeutics Corp. on January 31, 2004.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENOME THERAPEUTICS CORP.
By:	/s/    STEVEN M. RAUSHCER
Name: Steven M. Rauscher Title: President and Chief Executive Officer

Date: February 2, 2004

3

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release issued by Genome Therapeutics Corp. on January 31, 2004.

4